Company: IPSC
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001104659-25-002841
Chunk: 0

Company: Century Therapeutics, Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item      Results of Operations and Financial Condition  

On January 13, 2025, Century Therapeutics,
Inc. (the “ Company”) announced that, as of December 31, 2024, the Company had approximately $220 million of cash, cash equivalents
and investments. This unaudited, preliminary amount has been prepared by and is the responsibility of management. This amount is based
upon information available to management as of the date of this Current Report on Form 8-K and subject to completion of financial closing
procedures that could result in changes to the amount. Furthermore, this amount does not present all information necessary for an understanding
of the Company’s financial condition as of December 31, 2024. The Company’s independent registered public accounting firm,
Ernst & Young LLP, has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial data
and, accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. The Company’s
actual results for the year ended December 31, 2024 will be included in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2024 and may differ materially from the above estimate.

The information furnished pursuant to this Item 2.02 is intended to
be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended (the “ Securities Act”), or the Exchange Act, except as expressly
set forth by specific reference in such filing.